Fortress Biotech
FBIO
65 hedge funds and large institutions have $22.9M invested in Fortress Biotech in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 9 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
73% more call options, than puts
Call options by funds: $45K | Put options by funds: $26K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0.08% more ownership
Funds ownership: 0.88% → 0.96% (+0.08%)
2% less funds holding
Funds holding: 66 → 65 (-1)
26% less capital invested
Capital invested by funds: $31M → $22.9M (-$8.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.8M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$760K |
| 3 |
BlackRock
New York
|
+$440K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$391K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.43M |
| 2 |
Millennium Management
New York
|
-$210K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$126K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$110K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$106K |
FBIO Hedge Fund Activity: Q2 2018 in Review
65 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q2 2018, worth a combined $22.9M — down 26% from $31M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FBIO positions and 9 closed out — a net gain of 1 holder — while 27 added to existing stakes and 13 trimmed.
The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $1.8M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.43M sold.
- 65 institutional investors held Fortress Biotech (FBIO) as of Q2 2018, down from 66 in Q1 2018.
- Funds reported $22.9M of Fortress Biotech stock for Q2 2018, down 26% quarter-over-quarter.
- 10 funds opened new Fortress Biotech positions in Q2 2018 and 9 closed out, a net change of +1 holder.
- The largest Fortress Biotech buyer in Q2 2018 was Granite Point Capital Management, an estimated $1.8M added.
- The largest Fortress Biotech seller in Q2 2018 was Opaleye Management, an estimated $1.43M sold.
Based on aggregated 13F filings for Q2 2018.